Comprimés de citrate ferrique pour l'hyperphosphatémie chez les patients atteints de maladie rénale chronique sous hémodialyse

This study focuses on evaluating the effectiveness and safety of Ferric Citrate Tablets in treating high phosphorus levels, or hyperphosphatemia, in patients with Chronic Kidney Disease who are undergoing hemodialysis. The importance of this study lies in finding a potential new treatment option for managing hyperphosphatemia, a common complication in patients with kidney disease. This could significantly improve patient care and quality of life. The study is designed as a multicenter, randomized, open-label, parallel, phase III study. It involves a Screening/Washout period of 14 days and a Treatment/Observation period of 12 weeks. Patients who regularly undergo hemodialysis must stop using their current phosphorus binder before the Washout period. During the Treatment period, participants will be randomly assigned to either the Ferric Citrate Tablets group or the Sevelamer Carbonate Tablet group. The main goal is to measure the change in serum phosphorus levels at the end of the treatment compared to the beginning, to determine the effectiveness of the Ferric Citrate Tablets.